{
    "id": 8692,
    "name": "myeloid leukemia",
    "source": "DOID",
    "definition": "A leukemia that is located_in myeloid tissue. [url:http\\://en.wikipedia.org/wiki/Myeloid_leukemia]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "8879",
        "9066",
        "8910",
        "8878",
        "9126"
    ],
    "termId": "DOID:8692",
    "evidence": [
        {
            "id": 683,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CSFR1 Y571D conferred sensitivity to Gleevec (imatinib) in myeloid cell lines in culture (PMID: 18971950).",
            "molecularProfile": {
                "id": 952,
                "profileName": "CSF1R Y571D"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 397,
                    "pubMedId": 18971950,
                    "title": "Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18971950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1556,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, c-myb antisense oligonucleotide treatment demonstrated safety and resulted in stable disease in 12/18 patients with myeloid leukemia (PMID: 11713805).",
            "molecularProfile": {
                "id": 2678,
                "profileName": "MYB wild-type"
            },
            "therapy": {
                "id": 1866,
                "therapyName": "c-myb antisense oligonucleotide G4460",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1515,
                    "pubMedId": 11713805,
                    "title": "Technology evaluation: leukemia therapy, University of Pennsylvania.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11713805"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4585,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and SGI-1776 combination treatment did not inhibit proliferation of a myeloid cell line harboring BCR-ABL in culture (PMID: 26472029).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3549,
                "therapyName": "Ruxolitinib + SGI-1776",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Pim1 in MPL W515L-transformed myeloid cell lines induced resistance to growth inhibition by Jakafi (ruxolitinib) (PMID: 26472029).",
            "molecularProfile": {
                "id": 18599,
                "profileName": "MPL W515L PIM1 over exp"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7413,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse myeloid cells over expressing JAK2 V617F were resistant to Gleevec (imatinib) in culture (PMID: 21224473).",
            "molecularProfile": {
                "id": 591,
                "profileName": "JAK2 V617F"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse myeloid cells over expressing BCR-ABL1 demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7415,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse myeloid cells over expressing PDGFRA N659S demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473).",
            "molecularProfile": {
                "id": 24648,
                "profileName": "PDGFRA N659S"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7416,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing FIP1L1-PDGFRA in culture and prolonged survival in xenograft models (PMID: 21224473).",
            "molecularProfile": {
                "id": 7080,
                "profileName": "FIP1L1 - PDGFRA"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7417,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA Y849S in culture (PMID: 21224473).",
            "molecularProfile": {
                "id": 24650,
                "profileName": "PDGFRA Y849S"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7418,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA R748G in culture and prolonged survival in xenograft models (PMID: 21224473).",
            "molecularProfile": {
                "id": 24649,
                "profileName": "PDGFRA R748G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 E76K in culture (PMID: 29568093).",
            "molecularProfile": {
                "id": 9830,
                "profileName": "PTPN11 E76K"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15436,
                    "pubMedId": 29568093,
                    "title": "Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17452,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 D61Y in culture (PMID: 29568093).",
            "molecularProfile": {
                "id": 24129,
                "profileName": "PTPN11 D61Y"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15436,
                    "pubMedId": 29568093,
                    "title": "Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17453,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 A72V in culture (PMID: 29568093).",
            "molecularProfile": {
                "id": 12859,
                "profileName": "PTPN11 A72V"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15436,
                    "pubMedId": 29568093,
                    "title": "Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17454,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 inhibited Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 A72V in culture (PMID: 29568093).",
            "molecularProfile": {
                "id": 12875,
                "profileName": "PTPN11 E69K"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15436,
                    "pubMedId": 29568093,
                    "title": "Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of PTPN11 knock-out myeloid cells in culture (PMID: 29568093).",
            "molecularProfile": {
                "id": 26397,
                "profileName": "PTPN11 dec exp"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15436,
                    "pubMedId": 29568093,
                    "title": "Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02129101",
            "title": "Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                },
                {
                    "id": 1428,
                    "therapyName": "Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03164057",
            "title": "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 5153,
                    "therapyName": "Dexrazoxane",
                    "synonyms": null
                },
                {
                    "id": 1006,
                    "therapyName": "Daunorubicin",
                    "synonyms": null
                },
                {
                    "id": 1022,
                    "therapyName": "Idarubicin",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2206,
                    "therapyName": "Asparaginase",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 1740,
                    "therapyName": "Mitoxantrone",
                    "synonyms": null
                },
                {
                    "id": 650,
                    "therapyName": "Decitabine",
                    "synonyms": null
                },
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03214666",
            "title": "GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9469,
                    "therapyName": "GTB-3550 TriKE",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04260022",
            "title": "Study of HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (HQP1351CU101)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8237,
                    "therapyName": "HQP1351",
                    "synonyms": null
                }
            ]
        }
    ]
}